ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

ClinicalTrials.gov ID: NCT00146770

Public ClinicalTrials.gov record NCT00146770. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 9:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Multinational, Open-Label Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I

Study identification

NCT ID
NCT00146770
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Genzyme, a Sanofi Company
Industry
Enrollment
45 participants

Conditions and interventions

Interventions

  • Aldurazyme Biological
  • placebo Biological

Biological

Eligibility (public fields only)

Age range
Not listed
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2001
Primary completion
Feb 28, 2005
Completion
Feb 28, 2005
Last update posted
Apr 2, 2015

2001 – 2005

United States locations

U.S. sites
8
U.S. states
8
U.S. cities
8
Facility City State ZIP Site status
University of South Alabama Mobile Alabama 36604
Emory University School of Medicine Atlanta Georgia 30322
University of Rochester Rochester New York 14542
University of North Carolina at Chapel Hill Chapel Hill North Carolina 27599
Toledo Children's Hospital Toledo Ohio 43606
Merle West Medical Center Klamath Falls Oregon 97601
The Childrens Hospital of Philadelphia Philadelphia Pennsylvania 19104
Rhode Island Hospital Providence Rhode Island 02903

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00146770, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 2, 2015 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00146770 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →